Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
130 results about "Antiviral treatment" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antiviral therapy is often used by cancer patients to treat viral infections. Commonly used antiviral medications include acyclovir, famciclovir, ganciclovir, valacyclovir, and foscarnet.
Percutaneous delivery system
InactiveUS6211250B1Good substantivityAppropriate thicknessAntibacterial agentsAntimycoticsActive agentPharmacology
The invention relates to a substantially homogenous liquid composition capable of percutaneous delivery of one or more physiologically active agents, the composition including a rate modulating polymer, a volatile solvent and at least one physiologically active agent, said rate modulating polymer being selected to enable modulation of the rate of delivery of said physiologically active agent. Methods of percutaneous delivery of active agents and of prophylactic or therapeutic antimicrobial, antifungal or antiviral treatment using the compositions of the invention are also described.
Owner:STIEFEL RESEARCH AUSTRALIA PTY LTD
1′-substituted carba-nucleoside analogs for antiviral treatment
Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
Owner:GILEAD SCI INC
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
Provided are select imidazo[1,2-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substituents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.
Owner:GILEAD SCI INC
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
ActiveUS20120020921A1Exposure was also limitedEfficient extractionSaccharide with heterocyclic radicalsBiocidePhosphateSugar
Provided are prodrugs of pyrrolo[1,2-f][1,2,4]triazin-7-yl nucleoside phosphates wherein the 1′ position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections.
Owner:GILEAD SCI INC
Carba-nucleoside analogs for antiviral treatment
Owner:GILEAD SCI INC
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
Owner:GILEAD SCI INC
Nucleoside analogs for antiviral treatment
ActiveUS8324179B2Increasing cellular accumulation and retentionIncrease valueBiocideSugar derivativesPharmaceutical medicinePharmaceutical Substances
Owner:GILEAD SCI INC
Anti-viral treatment and assay to screenfor Anti-viral agent
InactiveUS20130085133A1Improve palatabilityImprove stabilityBiocideSugar derivativesCytopathic effectAntiviral drug
The present disclosure relates to novel compounds of formulas (1) through (19) and to a method for treating humans infected with a virus including various respiratory viruses such as members of the Paramyxoviridae family (respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), measles virus, and mumps virus) with a compound of formulas (1) through (19). The present disclosure also relates to a cytopathic effect (CPE)-based assay that will assess virus-induced CPE for screening of compounds for treating viral diseases or inhibiting a virus.
Owner:SOUTHERN RES INST & IP
Antiviral therapeutic agents
InactiveUS7994139B2Useful in preparationBiocideSaccharide with heterocyclic radicalsAnti-Carcinogenic AgentsPharmaceutical Substances
Owner:BIOCRYST PHARM INC
Carba-nucleoside analogs for antiviral treatment
Provided are imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
Owner:GILEAD SCI INC
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2′ position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.
Owner:GILEAD SCI INC
1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
ActiveUS8877733B2Inhibition of replicationHigh selectivityBiocideSugar derivativesViral infectionNucleoside Analogs
Owner:GILEAD SCI INC
Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
The present application provides nitrogen-containing heterocycle derivatives that are antiviral compounds that may be useful in the treatment of a viral infection. Compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) may be administered to a subject for antiviral therapy or prophylaxis.
Owner:TRANSTECH PHARMA
Carba-nucleoside analogs for antiviral treatment
ActiveUS20100203015A1Inhibition of replicationBiocideSaccharide with heterocyclic radicalsFuranPhosphate
Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.
Owner:GILEAD SCI INC
1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
ActiveUS20120263678A1Improve cell selectivityInhibition of replicationBiocideSugar derivativesPyrimidineNucleoside Analogs
Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.
Owner:GILEAD SCI INC
Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment
The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general formula (Z): The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula and their use as a medicine or to treat or prevent viral infections.
Owner:PUERSTINGER GERHARD +1
2'-substituted carba-nucleoside analogs for antiviral treatment
Provided are compounds of Formula I,as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.
Owner:GILEAD SCI INC
Compounds and methods for antiviral treatment
Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Owner:GILEAD SCI INC
Nucleoside analogs for antiviral treatment
ActiveUS20100104532A1Increasing cellular accumulationImprove retentionBiocideSugar derivativesMedicineTreated animal
The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals (e.g. humans).
Owner:GILEAD SCI INC
Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general formula (A): wherein the substituents are described in the specification. The invention also relates to processes for the preparation and screening of compounds according to the invention having above mentioned general formula and their use in the treatment or prophylaxis of viral infections.
![Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment](https://images-eureka.patsnap.com/patent_img/d2c7c479-7f8e-4e3d-bda5-797d372f229a/US20050222198A1-20051006-C00001.png "Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment")
![Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment](https://images-eureka.patsnap.com/patent_img/d2c7c479-7f8e-4e3d-bda5-797d372f229a/US20050222198A1-20051006-C00002.png "Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment")
![Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment](https://images-eureka.patsnap.com/patent_img/d2c7c479-7f8e-4e3d-bda5-797d372f229a/US20050222198A1-20051006-C00003.png "Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment")
Owner:PUERSTINGER GERHARD +1
Compounds and methods for antiviral treatment
Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Owner:GILEAD SCI INC
Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
InactiveUS20040072144A1Relieve symptomsEfficient multiplicationBiocideMicrobiological testing/measurementVirus multiplicationClinical trial
A method for alleviating chronic fatigue syndrome with the administration of antiviral agents. Based on clinical tests, chronic fatigue syndrome is a persistent herpes virus infection including incomplete virus multiplication and thus administration of antiviral agents are shown to alleviate the symptoms associated with the disorder. Based on therapeutic trials, patients receiving the recommended antiviral treatment, have experienced significant reduction or elimination of the symptoms associated with chronic fatigue syndrome. A method of diagnosis of the chronic fatigue syndrome is further disclosed.
Owner:LERNER A MARTIN
Pyrazolo[1,5-a]pyrimidines for antiviral treatment
The invention provides compounds of Formula I or Formula II:or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
![Pyrazolo[1,5-a]pyrimidines for antiviral treatment](https://images-eureka.patsnap.com/patent_img/65ebc2a7-5baa-4fc2-ae18-dcd04adfaafa/US08486938-20130716-C00001.png "Pyrazolo[1,5-a]pyrimidines for antiviral treatment")
![Pyrazolo[1,5-a]pyrimidines for antiviral treatment](https://images-eureka.patsnap.com/patent_img/65ebc2a7-5baa-4fc2-ae18-dcd04adfaafa/US08486938-20130716-C00002.png "Pyrazolo[1,5-a]pyrimidines for antiviral treatment")
![Pyrazolo[1,5-a]pyrimidines for antiviral treatment](https://images-eureka.patsnap.com/patent_img/65ebc2a7-5baa-4fc2-ae18-dcd04adfaafa/US08486938-20130716-C00003.png "Pyrazolo[1,5-a]pyrimidines for antiviral treatment")
Owner:GILEAD SCI INC
Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
InactiveUS20050244490A1Improve oral bioavailabilityLow pill burdenBiocideCarbohydrate active ingredients5-fluorocytidineIn vivo
The disclosed invention is a composition for and a method of treating a HIV infection in a host, such as a human, using a single, once a day, oral dose of β-D-D4FC in an enteric-coated tablet. The enterically coated β-D-D4FC increases the amount of the drug that remains in active form for use in inhibiting the HIV virus in vivo.
Owner:PHARMASSET
Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
ActiveUS20140147875A1Low indexOrganic active ingredientsHealth-index calculationDisease severityNon invasive
A Disease Severity Index (DSI) is provided for assessment of chronic liver disease in a patient using non-invasive liver function test results. A DSI was derived from non-invasive liver function test results based on hepatic blood flow. The DSI is used in methods for prediction of clinical outcomes, prediction of response to antiviral treatment, and assessment of progression of chronic liver diseases. Non-invasive methods to diagnose three distinct categories of patients with Primary Sclerosing Cholangitis (PSC) are provided. The methods can be used to diagnose PSC patients as Slow Progressors, Moderate Progressors and Rapid Progressors.
Owner:UNIV OF COLORADO THE REGENTS OF
Air decontamination equipment
InactiveUS20110223057A1Most efficientReduce volatilityGas treatmentDispersed particle separationAir decontaminationVirus processing
The present invention relates to an air decontamination equipment, from both odours or pollutants, and bacterial or viral loads. More particularly, the present invention relates to a decontaminating equipment (1) for the treatment of air, comprising a shell (2) which is divided in a first and a second compartments (3, 4), which are arranged in a contiguous position in any sequence order, in the second of said compartments (3, 4) suction means (6) being arranged, in which one of said first and second compartments (3, 4) is for the antibacterial / antiviral treatment of air, and one of said first and second compartments (3, 4) is for the photocatalytic treatment of air, and comprises UV illumination means (9), said first and second compartments (3, 4) comprising a material with antibacterial and antiviral activity and a material with photocatalytic activity, respectively.
Owner:NM TECH NANOMATERIALS & MICRODEVICES TECH
Nucleobase phosphonate analogs for antiviral treatment
ActiveUS20050059637A1Increasing cellular accumulationImprove retentionBiocideOrganic active ingredientsHigh concentrationAcquired immunodeficiency
The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and / or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.
Owner:GILEAD SCI INC
Topical pharmaceutical bases for preventing viral diseases
ActiveUS9775872B2Improve permeabilityImprove propertiesPharmaceutical delivery mechanismAnhydride/acid/halide active ingredientsViral diseaseAntiviral treatment
The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.
Owner:PROFESSIONAL COMPOUNDING CENTS OF AMERICA PCCA
Antiviral therapeutic agents
InactiveUS20090227524A1Useful in preparationBiocideSaccharide with heterocyclic radicalsAnticarcinogenCombinatorial chemistry
The invention provides compounds of Formula I:as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and / or as anti-cancer agents.
Owner:BIOCRYST PHARM INC
Anti-virus therapy for respiratory diseases
The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose.
Owner:UNIV OF SOUTHAMPTON
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com